BACKGROUND Dry eye syndrome(DES)after diabetic cataract surgery can seriously affect the patient’s quality of life.Therefore,effective alleviation of symptoms in patients with this disease has important clinical sign...BACKGROUND Dry eye syndrome(DES)after diabetic cataract surgery can seriously affect the patient’s quality of life.Therefore,effective alleviation of symptoms in patients with this disease has important clinical significance.AIM To explore the clinical effect of recombinant human epidermal growth factor(rhEGF)plus sodium hyaluronate(SH)eye drops on DES after cataract surgery in patients with diabetes.METHODS We retrospectively evaluated 82 patients with diabetes who experienced DES after cataract surgery at Tianjin Beichen Hospital,Affiliated Hospital of Nankai University between April 2021 and April 2023.They were classified into an observation group(42 cases,rhEGF+SH eye drops)and a control group(40 cases,SH eye drops alone),depending on the different treatment schemes.The therapeutic efficacy,dry eye symptom score,tear film breakup time(TFBUT),basic tear secretion score[assessed using Schirmer I test(SIt)],corneal fluorescein staining(FL)score,tear inflammatory markers,adverse reactions during treat-ment,and treatment satisfaction were compared between the two groups.RESULTS Therapeutic efficacy was higher in the observation group compared with the control group.Both groups showed improved TFBUT and dry eye,as well as improved SIt and FL scores after treatment,with a more pronounced improvement in the observation group.Although no marked differences in adverse reactions were observed between the two groups,treatment satisfaction was higher in the observation group.CONCLUSION rhEGF+SH eye drops rendered clinical benefits to patients by effectively ameliorating dry eye and visual impairment with favorable efficacy,fewer adverse reactions,and high safety levels.Thus,this treatment should be promoted in clinical practice.展开更多
目的:系统评价玻璃酸钠联合复方倍他米松对比玻璃酸钠治疗膝关节骨性关节炎(KOA)的疗效,为临床用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、Web of Science、中国知网数据库、万方数据库、维普数据库、百度学术...目的:系统评价玻璃酸钠联合复方倍他米松对比玻璃酸钠治疗膝关节骨性关节炎(KOA)的疗效,为临床用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、Web of Science、中国知网数据库、万方数据库、维普数据库、百度学术数据库,收集玻璃酸钠联合复方倍他米松(观察组)对比玻璃酸钠(对照组)治疗KOA的随机对照试验(RCT)。筛选文献、提取资料后采用Jadad量表对纳入文献质量进行评价,采用Rev Man 5.3软件进行Meta分析。结果:共纳入24项RCT,共计2 929例患者。Meta分析结果显示,观察组患者总有效率[OR=5.33,95%CI(3.85,7.38),P<0.000 01]、美国特种外科医院膝关节评分[SMD=1.63,95%CI(1.32,1.93),P<0.000 01]、膝关节功能评分[SMD=1.22,95%CI(0.84,1.59),P<0.000 01]均显著高于对照组,视觉模拟评分[SMD=-1.44,95%CI(-1.76,-1.11),P<0.000 01]显著低于对照组。结论:玻璃酸钠联合复方倍他米松治疗KOA的疗效显著优于单用玻璃酸钠,且能显著改善膝关节功能。展开更多
目的观察普瑞巴林胶囊联合玻璃酸钠注射液治疗骨质疏松症合并膝关节骨性关节炎的效果。方法选取2016年1月至2019年3月于深圳市第二人民医院治疗的骨质疏松症合并膝关节骨性关节炎患者92例为研究对象,按照随机数字表法将入选患者分为观...目的观察普瑞巴林胶囊联合玻璃酸钠注射液治疗骨质疏松症合并膝关节骨性关节炎的效果。方法选取2016年1月至2019年3月于深圳市第二人民医院治疗的骨质疏松症合并膝关节骨性关节炎患者92例为研究对象,按照随机数字表法将入选患者分为观察组和对照组,每组各46例。对照组患者采用玻璃酸钠注射液治疗,观察组患者在对照组基础上联合普瑞巴林胶囊治疗,两组患者均连续治疗6周。比较两组患者临床效果、治疗前后视觉模拟评分法(visual analogue scale,VAS)和西安大略和麦克玛斯特大学骨关节炎指数(the Western Ontario and McMaster Universities osteoarthritis index,WOMAC)评分、膝关节活动度。结果观察组患者治疗总有效率显著高于对照组(P<0.05)。两组患者治疗后VAS评分和WOMAC评分均显著低于本组治疗前(均P<0.05),膝关节活动度均显著大于本组治疗前(均P<0.05);观察组患者治疗后VAS评分和WOMAC评分均显著低于对照组(均P<0.05),膝关节活动度显著大于对照组(P<0.05)。结论普瑞巴林胶囊联合玻璃酸钠注射液治疗骨质疏松症合并膝关节骨性关节炎效果显著,能有效缓解患者关节疼痛,改善关节功能,具有良好的临床应用价值。展开更多
基金Supported by Tianjin Health Research Project,No.TJWJ2023MS062。
文摘BACKGROUND Dry eye syndrome(DES)after diabetic cataract surgery can seriously affect the patient’s quality of life.Therefore,effective alleviation of symptoms in patients with this disease has important clinical significance.AIM To explore the clinical effect of recombinant human epidermal growth factor(rhEGF)plus sodium hyaluronate(SH)eye drops on DES after cataract surgery in patients with diabetes.METHODS We retrospectively evaluated 82 patients with diabetes who experienced DES after cataract surgery at Tianjin Beichen Hospital,Affiliated Hospital of Nankai University between April 2021 and April 2023.They were classified into an observation group(42 cases,rhEGF+SH eye drops)and a control group(40 cases,SH eye drops alone),depending on the different treatment schemes.The therapeutic efficacy,dry eye symptom score,tear film breakup time(TFBUT),basic tear secretion score[assessed using Schirmer I test(SIt)],corneal fluorescein staining(FL)score,tear inflammatory markers,adverse reactions during treat-ment,and treatment satisfaction were compared between the two groups.RESULTS Therapeutic efficacy was higher in the observation group compared with the control group.Both groups showed improved TFBUT and dry eye,as well as improved SIt and FL scores after treatment,with a more pronounced improvement in the observation group.Although no marked differences in adverse reactions were observed between the two groups,treatment satisfaction was higher in the observation group.CONCLUSION rhEGF+SH eye drops rendered clinical benefits to patients by effectively ameliorating dry eye and visual impairment with favorable efficacy,fewer adverse reactions,and high safety levels.Thus,this treatment should be promoted in clinical practice.
文摘目的:系统评价玻璃酸钠联合复方倍他米松对比玻璃酸钠治疗膝关节骨性关节炎(KOA)的疗效,为临床用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、Web of Science、中国知网数据库、万方数据库、维普数据库、百度学术数据库,收集玻璃酸钠联合复方倍他米松(观察组)对比玻璃酸钠(对照组)治疗KOA的随机对照试验(RCT)。筛选文献、提取资料后采用Jadad量表对纳入文献质量进行评价,采用Rev Man 5.3软件进行Meta分析。结果:共纳入24项RCT,共计2 929例患者。Meta分析结果显示,观察组患者总有效率[OR=5.33,95%CI(3.85,7.38),P<0.000 01]、美国特种外科医院膝关节评分[SMD=1.63,95%CI(1.32,1.93),P<0.000 01]、膝关节功能评分[SMD=1.22,95%CI(0.84,1.59),P<0.000 01]均显著高于对照组,视觉模拟评分[SMD=-1.44,95%CI(-1.76,-1.11),P<0.000 01]显著低于对照组。结论:玻璃酸钠联合复方倍他米松治疗KOA的疗效显著优于单用玻璃酸钠,且能显著改善膝关节功能。
文摘目的观察普瑞巴林胶囊联合玻璃酸钠注射液治疗骨质疏松症合并膝关节骨性关节炎的效果。方法选取2016年1月至2019年3月于深圳市第二人民医院治疗的骨质疏松症合并膝关节骨性关节炎患者92例为研究对象,按照随机数字表法将入选患者分为观察组和对照组,每组各46例。对照组患者采用玻璃酸钠注射液治疗,观察组患者在对照组基础上联合普瑞巴林胶囊治疗,两组患者均连续治疗6周。比较两组患者临床效果、治疗前后视觉模拟评分法(visual analogue scale,VAS)和西安大略和麦克玛斯特大学骨关节炎指数(the Western Ontario and McMaster Universities osteoarthritis index,WOMAC)评分、膝关节活动度。结果观察组患者治疗总有效率显著高于对照组(P<0.05)。两组患者治疗后VAS评分和WOMAC评分均显著低于本组治疗前(均P<0.05),膝关节活动度均显著大于本组治疗前(均P<0.05);观察组患者治疗后VAS评分和WOMAC评分均显著低于对照组(均P<0.05),膝关节活动度显著大于对照组(P<0.05)。结论普瑞巴林胶囊联合玻璃酸钠注射液治疗骨质疏松症合并膝关节骨性关节炎效果显著,能有效缓解患者关节疼痛,改善关节功能,具有良好的临床应用价值。
